Understanding phenobarbital, butalbital, secobarbital dependence, pharmacology, withdrawal, and evidence-based residential treatment at Phuket Island Rehab.
Clinically reviewed by Dr. Ponlawat Pitsuwan, Physician and Addiction Medicine Specialist, Phuket Island Rehab.
Barbiturates are a class of central nervous system depressants that bind to the GABA-A receptor, the same complex that benzodiazepines and alcohol act on. Once the dominant sedative-hypnotics of the twentieth century, they have largely been replaced by benzodiazepines because of their narrow therapeutic index and high overdose lethality. The remaining clinical uses are phenobarbital for seizure control, butalbital combined with acetaminophen or aspirin for tension headache, and short-acting agents such as thiopental or methohexital in anaesthesia. Dependence is physical and behavioural, withdrawal can be fatal, and detoxification must be medically supervised. At Phuket Island Rehab, we treat barbiturate dependence with a structured phenobarbital substitution taper, parallel therapy, and a residential setting that removes patients from the prescribing relationship.
What are barbiturates?
Barbiturates are commonly prescribed for epilepsy, used to help with seizure control, and barbiturates are used historically as anti-anxiety agents and sleeping pills. Prescriptions for barbiturates have declined since the 1970s but have not disappeared. Barbiturates are a class of drugs, specifically a family of sedative-hypnotic medications, central nervous system depressants, and a class of drugs known as a class of drugs called barbiturates, derived from barbituric acid, first synthesised in 1864 and introduced into clinical use as Veronal in 1903. The barbiturate drug class is a depressant prescription drug class with high addiction potential. For most of the twentieth century barbiturates were the dominant class of prescription sleeping pill, anti-anxiety agent, and anticonvulsant. By the 1970s they had been largely displaced by benzodiazepines, which act on the same neurochemical system but are far harder to die from. Today the different types of barbiturates still in regular use are a much smaller list, and a brief list of types of barbiturates that barbiturates include phenobarbital for epilepsy and neonatal withdrawal, butalbital in combination headache products such as Fioricet and Fiorinal, primidone for tremor, and short-acting injectables such as thiopental and methohexital in anaesthesia and procedural sedation. Pentobarbital and secobarbital remain available but are now uncommon outside specific veterinary, anaesthetic, or end-of-life contexts. Drug addiction to barbiturates remains a recognised problem and barbiturate abuse continues to be reported, particularly among older adults and patients on long-term butalbital. Barbiturates are a psychoactive drug and a controlled prescription drug, and they are often classified as drugs of abuse alongside benzodiazepines and opioids. They are not a stimulant; they are sedatives that slow brain activity.
Patients arrive at our clinic with barbiturate dependence from three main routes. The first is long-term phenobarbital use, sometimes for decades, in adults with seizure disorders or as legacy treatment for alcohol withdrawal; phenobarbital is often used to manage these long-term conditions and is prescribed to treat both indications. The second is butalbital-containing headache medication, which is widely prescribed in the United States despite being unavailable in much of Europe, and which produces both medication overuse headache and physical dependence in patients who take it daily for years. Doctors prescribe barbiturates less often now than they did in the 1960s, but enough patients remain on prescriptions for barbiturates that the problem is far from historical; even when no clinician would prescribe barbiturates today for a new indication, the existing prescriptions for barbiturates accumulate over years. The third is recreational or self-medicated use of street-supplied barbiturates, sometimes mixed with benzodiazepines, alcohol, or opioids, where the pattern looks more like classic sedative addiction. Drug and alcohol services treating sedative dependence routinely encounter both ends of this spectrum, and a sensible treatment program for either group has to start with an honest map of all the substances on board.
How barbiturates work in the brain
The GABA-A receptor is the principal inhibitory receptor in the human brain. When gamma-aminobutyric acid binds to it, the channel opens, chloride ions enter the neuron, and the cell becomes harder to fire. Most sedative drugs work by amplifying this signal in some way. Benzodiazepines bind to a specific site on the GABA-A receptor and increase the frequency of channel opening when GABA is present. Barbiturates bind to a different site and increase the duration of channel opening. At higher doses, barbiturates can open the channel directly even without GABA being present. This last property is what makes them so much more dangerous than benzodiazepines: there is no built-in ceiling. Doubling the dose continues to deepen sedation past the point at which breathing stops.
Barbiturates differ in how quickly they cross the blood-brain barrier and how long they linger. Ultra-short-acting agents such as thiopental and methohexital reach the brain in seconds and wear off within minutes, which is why they are used for the induction of anaesthesia. Short-to-intermediate-acting agents such as pentobarbital, secobarbital, and butalbital last several hours and produce the kind of sedation that historically drove their use as sleeping pills. Long-acting agents such as phenobarbital and primidone have half-lives measured in days, which is what makes phenobarbital useful for seizure control and for treating withdrawal from other sedatives. The longer the half-life, the smoother the withdrawal but the harder the drug is to clear in overdose.
| Agent | Typical use | Half-life | Notes |
|---|---|---|---|
| Phenobarbital | Epilepsy, neonatal withdrawal, sedative detox | 80 to 120 hours | Long-acting, slow off-set, used in supervised tapers |
| Butalbital (in Fioricet, Fiorinal) | Tension headache combinations | 35 hours | Intermediate; common path to dependence in chronic headache patients |
| Pentobarbital | Refractory status epilepticus, veterinary, end-of-life | 15 to 50 hours | Short-to-intermediate, narrow safety margin |
| Secobarbital (Seconal) | Insomnia (historical), end-of-life | 15 to 40 hours | Once a major sleeping pill, now uncommon |
| Thiopental, methohexital | Anaesthetic induction | Minutes | IV only, hospital use |
Why barbiturates were replaced by benzodiazepines
Two clinical realities pushed barbiturates aside in the 1960s and 1970s. The first was the introduction of chlordiazepoxide in 1960 and diazepam in 1963. The benzodiazepines delivered similar anxiolysis and sedation without the same cardiac and respiratory risk at supra-therapeutic doses. The second was the accumulating evidence that barbiturates were responsible for a disproportionate share of accidental and intentional overdose deaths in the same era. By the time the United States passed the Controlled Substances Act in 1970, secobarbital, pentobarbital, and amobarbital were schedule II drugs and the benzodiazepines were taking over the sedative market.
The displacement was not total. Phenobarbital remained one of the cheapest and most effective anticonvulsants and stayed on the World Health Organization’s essential medicines list, where it still sits today. Butalbital combinations continued to be prescribed for tension headache, particularly in the United States. Thiopental and methohexital remained anaesthetic mainstays. The clinical legacy is that the patients who do present with barbiturate dependence today are more likely to be on a single medication for a specific indication than to be using a barbiturate as a drug of abuse, although both patterns exist.
How barbiturate addiction develops
Physical dependence on barbiturates develops on a schedule comparable to alcohol or benzodiazepines. Daily therapeutic dosing for two to four weeks is enough to establish tolerance and the beginnings of a withdrawal syndrome if the drug is stopped abruptly. Daily butalbital use for chronic headache, even at the prescribed dose, regularly produces dependence within months. Long-term phenobarbital use for epilepsy almost always produces dependence by the time anyone considers withdrawing it, which is one reason these patients should not stop the medication on their own.
Addiction, in the behavioural sense defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, is a separate question. A patient who takes phenobarbital exactly as prescribed for seizure control, who never escalates the dose and never combines it inappropriately, is physically dependent but does not meet criteria for substance use disorder. A patient who runs out of butalbital early, who borrows from family, who takes the medication for emotional regulation rather than headache, or who combines it with alcohol or opioids to amplify the effect is on the disordered-use trajectory. The behavioural shift is what defines addiction; physical dependence on its own does not.
Three patterns drive barbiturate misuse in practice. The first is medication overuse in chronic headache patients, where increasing doses chase a moving headache target and the medication itself begins to drive a daily cycle of rebound pain and dosing. The second is sedative cross-use, particularly among patients with alcohol use disorder, who discover that barbiturates blunt withdrawal symptoms and produce a familiar disinhibition. The third is intentional polydrug use, where barbiturates are added to opioids, benzodiazepines, or alcohol for amplified sedation, a combination with a high overdose death rate.
Risk factors and signs of a problem
Risk for moving from prescribed barbiturate use to disordered use is higher in patients with co-occurring alcohol use disorder, a history of benzodiazepine or opioid misuse, untreated depression or anxiety, chronic pain or chronic headache syndromes, and access to multiple prescribers. Older adults are at particular risk because phenobarbital and butalbital accumulate in the body, interact with many other medications, and produce confusion and falls that are often misread as dementia rather than drug effect.
Behavioural signs that family or a prescribing clinician should not ignore include running out of medication earlier than scheduled, escalating the dose without consultation, requesting early refills or reporting lost prescriptions, taking the medication for indications it was not prescribed for, combining the medication with alcohol or other sedatives, hiding use, and the appearance of withdrawal symptoms between doses. Cognitive slowing, slurred speech, ataxia, and emotional blunting in someone on long-term barbiturate therapy are clinical signals that the dose, the indication, or the substance itself needs reassessment.
Barbiturate withdrawal
Barbiturate withdrawal is a medical emergency. Like alcohol and benzodiazepine withdrawal, it is one of the small number of substance withdrawal syndromes that can be fatal if untreated. The mechanism is the same: years of chronic GABA-A potentiation have been compensated for by reductions in tonic inhibition and upregulation of excitatory glutamatergic signalling. When the barbiturate is removed, the unopposed glutamate drive produces autonomic hyperactivity, anxiety, tremor, hallucinations, and, in severe cases, generalised seizures and a delirium clinically indistinguishable from delirium tremens.
Symptoms typically begin 8 to 16 hours after the last dose of a short-acting barbiturate such as butalbital or secobarbital, with peak severity at 48 to 72 hours. With phenobarbital, the long half-life delays onset to several days and prolongs the course, sometimes into the second or third week. The early phase brings anxiety, insomnia, sweating, tremor, nausea, raised blood pressure, and tachycardia. The middle phase, between days two and five for short-acting agents, is when seizures and delirium most commonly appear. Seizures are typically generalised tonic-clonic and may occur in clusters. Delirium presents with agitation, disorientation, visual hallucinations, and severe autonomic instability.
| Phase | Timing after last dose (short-acting) | Typical features |
|---|---|---|
| Early | 8 to 24 hours | Anxiety, insomnia, tremor, sweating, nausea, hypertension, tachycardia |
| Peak | 24 to 72 hours | Risk of generalised seizures, hallucinations, delirium, severe autonomic instability |
| Resolution | Day 5 to day 10 | Symptoms ease, sleep and mood remain disturbed for weeks |
Overdose, interactions, and the polydrug picture
Barbiturate overdose is fundamentally a respiratory event. As blood levels rise, the brainstem centres that drive breathing are progressively suppressed until ventilation stops. There is no specific antidote in the way naloxone reverses opioid overdose; supportive care, airway protection, mechanical ventilation, and alkalinisation of the urine to enhance phenobarbital clearance are the available tools. The therapeutic window between a sedating dose and a fatal dose is narrow, particularly for short-acting agents, and it shrinks further with concurrent alcohol, benzodiazepines, or opioids.
Pharmacologically, barbiturates are among the most potent inducers of the cytochrome P450 family of liver enzymes, particularly CYP3A4 and CYP2C9. Chronic phenobarbital lowers blood levels of many other medications: oral contraceptives, warfarin, certain antiretrovirals, immunosuppressants, and some chemotherapy agents. Patients are sometimes surprised to discover that their barbiturate is responsible for a contraceptive failure or a sub-therapeutic warfarin level. Conversely, drugs that inhibit these enzymes, or sudden cessation of the barbiturate, can produce abrupt rises in concentrations of co-administered medications.
Treatment at Phuket Island Rehab
Patients arrive at our treatment center with barbiturate dependence in several patterns. Some have been on phenobarbital for decades and want to step down under supervision, often because cognitive side effects have begun to outweigh seizure-control benefit. Some are dependent on butalbital after years of daily Fioricet for headache, and many will experience withdrawal symptoms if they stop without help. Some are using barbiturates as part of a polydrug pattern alongside benzodiazepines, alcohol, or opioids. Each pattern requires a different sequencing of medication and therapy. Our treatment options include inpatient detox, structured residential rehabilitation, partial hospitalization for patients stepping down from residential, and intensive outpatient programs for those who can return home; the level of care is matched to the severity of dependence and to co-occurring conditions. Treatment facilities that offer this full continuum, including formal outpatient treatment and outpatient programs, are best placed to deliver a barbiturate addiction treatment program that lasts. Patients who are addicted to barbiturates and struggling with addiction often need both medical detoxification and the behavioural health support that comes with a structured addiction treatment program. The first task of the admitting physician is to map the full substance picture honestly rather than treat the barbiturate in isolation. Medical professionals and health professional staff coordinate the plan, which addresses the effects of barbiturates on cognition, mood, and physical health.
Our standard approach to barbiturate detoxification is phenobarbital substitution and taper, regardless of which specific barbiturate the patient is dependent on. This is the same approach used in clinical guidance for sedative detoxification, and it works for the same reason it works for benzodiazepines: phenobarbital’s long half-life produces a smooth, predictable taper and protects against withdrawal seizures even if a dose is missed. We calculate an initial phenobarbital equivalent based on the patient’s prior daily intake, stabilise on that dose, and then reduce by approximately 10 percent every two to three days, adjusting the pace by symptom severity rather than by calendar.
Therapy runs in parallel from day one. Medical detox and drug detoxification are one task; recovery is another, and they cannot be sequenced. Patients work with our counsellors on the underlying pattern that brought them to sedatives in the first place, on relapse prevention for the specific cross-tolerance and cross-vulnerability to alcohol and benzodiazepines that characterises post-barbiturate recovery, and on the chronic pain or anxiety conditions that often drove the original prescription. For butalbital-dependent patients, we work closely with patients on a non-barbiturate plan for headache management before discharge. Patients with co-occurring mental health conditions, addiction and mental health overlap, or alcohol withdrawal syndrome alongside the barbiturate dependence are managed in a coordinated way by a mental health professional and our medical team. The right treatment for each patient depends on the severity of the addiction, the type of barbiturate involved, and the duration of use. Barbiturate addiction treatment and rehab options at our facility include detox, inpatient treatment, and step-down care; addiction treatment options available also extend to inpatient and outpatient care for patients who need a longer recovery arc. Some barbiturates have street names such as goof balls or Tuinal, and patients are sometimes embarrassed to disclose use under those names; we ask without judgement. Common side effects during taper include somnolence, slowed cognition, and gastrointestinal upset. Symptoms of barbiturate withdrawal associated with barbiturate dependence are predictable enough that we can prepare patients in advance.
Treatment programs and rehab facility options
Barbiturates are most commonly encountered today in three settings: long-term phenobarbital for epilepsy, butalbital for headache, and short-acting injectables in anaesthesia. Barbiturates are a group of drugs that belong to a class of sedative-hypnotics, and barbiturate addiction involves both physical dependence and a behavioural pattern of compulsive use. Patients dependent on barbiturates and physically dependent on barbiturates can experience dangerous withdrawal symptoms and dangerous side effects, including seizures. Barbiturates are often used as anticonvulsants and were once used to treat anxiety; barbiturates can also be used to treat status epilepticus. Withdrawal from barbiturates and symptoms of withdrawal require medical supervision. Signs of barbiturate abuse or addiction include dose escalation and early refills. Mental health care, addiction and overdose prevention, and a range of treatment centres deliver drug and alcohol treatment for this population. Treatment options for barbiturate dependence include detox, residential rehab, and aftercare; patients also benefit from advice from a mental health professional and from care coordination across services. Patients looking for barbiturate addiction treatment and rehab will find that treatment programs differ widely in quality. A good rehab facility offers more than detox; it offers a barbiturate addiction treatment and rehab pathway that combines medical detox, structured therapy, and stepped continuing care. Treatment for barbiturate misuse, treatment for barbiturate dependence, and broader treatment for barbiturate-related addiction and overdose all overlap. Our standard programme is built around a residential phenobarbital substitution taper, parallel therapy, addiction and mental health support for co-occurring conditions, and a clear post-discharge plan. Patients who want to stop taking the medication safely should not stop without help, and they should look for a programme that does not promise an instant cure. Drug treatment for barbiturate dependence is a real medical event that needs real time.
Why international clients come to Thailand
Patients from the United States, the United Kingdom, Australia, and continental Europe travel to Phuket Island Rehab for barbiturate detoxification for several reasons that are specific to this drug class. The first is the long-standing nature of the prescription. A patient who has been on phenobarbital or butalbital for ten or twenty years has often been seeing the same prescriber, in the same clinic, alongside the same pharmacy, for that entire time. Geographic distance is sometimes the only practical way to break that pattern and make the taper actually happen.
The second is privacy. Many of our clients are professionals, executives, or public figures whose careers would not survive the kind of disclosure that comes with domestic rehab. Treatment in Phuket is discreet by default, and the climate, food, and pace of the island reduce the institutional feel that so many patients dread.
The third is cost. A month of structured residential care in Phuket, including medical detox, therapy, accommodation, food, and excursions, costs a fraction of the equivalent programme in the United States, the United Kingdom, or Australia. For self-funded patients, that difference often translates into the ability to commit to a longer stay, which is the single strongest predictor of long-term outcome in sedative use disorder.
When use of barbiturates has become more than prescribed
Many of the people who reach out to our team are not in obvious crisis. They are still functional, still showing up to work, still seeing the same prescriber. What has changed is that they no longer feel they are choosing the medication; the medication is choosing them. Dose increases happen and never quite reverse. The Fioricet bottle empties earlier in the month. The phenobarbital dose has crept up over the years without anyone quite intending it. Drinking is heavier than it used to be, and sleep is worse than it has been in years. If you are looking for treatment for barbiturate dependence, the next step is to get help from a clinician who is honest about how the drug works and what coming off it really takes. Treatment for barbiturate addiction is not the same as treatment for alcohol or opioid use disorder, even though the medications often overlap. Patients addicted to barbiturates rarely match the stereotype of a person abusing barbiturates illicitly; most are quietly using the drug exactly as it was prescribed and have not realised that misusing barbiturates can happen inside the boundaries of a legitimate prescription. Drug addiction can be subtle. Recognising the abuse of barbiturates in oneself is the hardest step.
If that pattern is familiar, the question is no longer whether the prescription was originally appropriate. It is whether the current pattern is moving in the direction the patient wants their life to go. A conversation with an addiction specialist, a properly supervised phenobarbital taper, and time away from the environment that has shaped the habit are reasonable next steps, and they are not a failure of the original medical decision.
Summary
Barbiturates were once the dominant sedative-hypnotic class and have left a clinical legacy that still produces dependence in patients today, most often through long-term phenobarbital for epilepsy or butalbital combinations for headache. The pharmacology is GABA-A potentiation without the partial-ceiling protection of benzodiazepines, which is why overdose remains lethal and why withdrawal can be fatal if unsupervised. The clinical task is not to demonise the molecule, which still has legitimate indications, but to recognise when prescribed use has slipped into dependence or disordered use and to taper safely under medical care. A residential phenobarbital substitution taper, parallel therapy, and time away from the prescribing environment are the components of a recovery that lasts beyond the medication.
As our physician Dr. Ponlawat Pitsuwan puts it, “Phenobarbital is one of the oldest and most useful drugs in medicine. It is also one of the easiest to slip into dependence with, because the dose-response curve is flat in the therapeutic range and the half-life means a patient never quite feels withdrawal between doses. By the time the cognitive cost becomes obvious, the patient is on a daily medication they cannot stop alone. Our job is to make that step down possible.”
Frequently asked questions
What are barbiturates used to treat?
Barbiturates are used to treat epilepsy, neonatal opioid withdrawal, status epilepticus, severe headache combinations (in butalbital-containing products such as Fioricet and Fiorinal), and for anaesthesia induction. Historically they were also used to treat anxiety and insomnia, but those uses have been almost entirely replaced by benzodiazepines and other newer agents. Some practitioners still prescribe phenobarbital for alcohol withdrawal management. Beyond these legitimate indications, recreational drug use of barbiturates persists in some populations, though far less than in the 1960s and 1970s when barbiturates were among the most common drugs of abuse.
What are common examples of barbiturates still in use today?
The barbiturates most likely to be encountered in modern clinical practice are phenobarbital, used for epilepsy and neonatal withdrawal; butalbital, the active sedative in headache combination products such as Fioricet and Fiorinal; primidone, used for essential tremor and partially metabolised to phenobarbital; pentobarbital, used for refractory status epilepticus and in some end-of-life contexts; and the short-acting injectables thiopental and methohexital, used in anaesthesia. Secobarbital and amobarbital, once major sleeping pills, are now uncommon outside specific niche uses. Older barbiturates such as Veronal and Luminal are largely historical.
Is butalbital addictive?
Yes. Butalbital is a short-to-intermediate-acting barbiturate and produces the same physical dependence and addiction risks as other barbiturates. The pattern that most commonly leads to butalbital addiction is daily or near-daily use of Fioricet or Fiorinal for chronic tension headache. Patients often begin within prescribed limits and find over months or years that the medication has become necessary not just for headache relief but for sleep, anxiety, and general daily function. Daily intake of more than four tablets is a clinical red flag. Withdrawal from chronic butalbital can produce seizures and should not be attempted without medical supervision.
How is barbiturate withdrawal treated?
The standard medical approach is substitution onto phenobarbital and a slow, supervised taper. The clinician calculates a phenobarbital equivalent dose based on the patient’s prior intake, stabilises the patient on that dose for one to three days, and then reduces by approximately 10 percent every two to three days. The long half-life of phenobarbital protects against missed-dose seizures and produces a far smoother course than tapering directly from a short-acting agent. Vital signs, mental status, and seizure risk are monitored throughout. Most tapers run two to four weeks for short-acting barbiturates and longer for patients coming off chronic phenobarbital.
Can you overdose on barbiturates alone?
Yes, and the overdose is often fatal. Unlike opioids, where naloxone can reverse respiratory depression, there is no specific antidote for barbiturate overdose. Management is supportive: airway protection, mechanical ventilation, intravenous fluids, urinary alkalinisation to speed phenobarbital clearance, and intensive care monitoring. The therapeutic window between sedation and respiratory arrest is narrow, particularly for short-acting agents, and it shrinks further when alcohol, benzodiazepines, or opioids are also on board. Most modern barbiturate deaths involve combinations rather than a single agent.
How are barbiturates and benzodiazepines different?
Both act on the GABA-A receptor complex, but at different binding sites and with different consequences. Benzodiazepines increase the frequency of channel opening when GABA is already present, which produces a partial ceiling on sedation: doubling the dose does not endlessly double the effect. Barbiturates increase the duration of channel opening and, at higher doses, can open the channel directly without GABA being present. That last property is why barbiturate overdose is so much more often fatal. Both classes produce dependence; both have potentially fatal withdrawal; both are best detoxed with a supervised phenobarbital taper.
Do I need residential treatment, or can I taper from home?
Some stable, motivated patients with strong support and a willing prescriber successfully taper barbiturates in outpatient care, particularly from low-dose phenobarbital. Residential treatment becomes the better option when daily intake has been high, when previous outpatient attempts have stalled, when alcohol or other sedatives are part of the picture, when the patient has had a previous withdrawal seizure, when underlying mental health conditions are unstable, or when the home environment is where the original use developed. Because barbiturate withdrawal can produce seizures, the safety case for medical supervision is stronger here than for many other substances.
Sources
World Health Organization. WHO Model List of Essential Medicines, 23rd list, 2023. Phenobarbital listing and clinical rationale. who.int.
National Institute on Drug Abuse. Prescription central nervous system depressants research report. nida.nih.gov.
Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol (TIP) 45: Detoxification and Substance Abuse Treatment. samhsa.gov.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fifth edition, text revision. Sedative, hypnotic, or anxiolytic use disorder, criteria and severity ratings.
National Health Service. Information on phenobarbital for epilepsy. nhs.uk.
U.S. Food and Drug Administration. Prescribing information for butalbital-containing combination products and phenobarbital. fda.gov.
Related reading on this site
- Barbiturates examples
- Barbiturates list
- Barbiturate rehab
- Barbiturate-related asphyxia
- Butalbital dose for sleep
- Is butalbital addictive?
- Is a quaalude a barbiturate?
- Benzodiazepine addiction
- Xanax addiction
- Alcohol addiction
- Medical detox at Phuket Island Rehab
Barbiturate, barbiturate drug, phenobarbital, butalbital, Fioricet, Fiorinal, secobarbital, Seconal, pentobarbital, amobarbital, primidone, thiopental, methohexital, GABA-A receptor, chloride channel, benzodiazepine, alcohol, alcohol (drug), alcohol use disorder, sedative use disorder, depressant, central nervous system depressant, psychoactive drug, prescription drug, medical prescription, narcotic, illicit, stimulant, DSM-5, CYP3A4, CYP2C9, cytochrome P450 induction, status epilepticus, generalised tonic-clonic seizure, delirium, respiratory depression, narrow therapeutic index, polydrug overdose, medication overuse headache, chronic tension headache, drug withdrawal, drug rehabilitation, signs and symptoms, substance dependence, substance use disorder, drugs of abuse, mental disorder, mental health, health professional, behavioral health, emergency department, level of care, adolescence, Al-Anon/Alateen, World Health Organization essential medicines list, U.S. Food and Drug Administration, National Institute on Drug Abuse, SAMHSA, National Health Service, Phuket Island Rehab.